47. Buerger disease Clinical trials / Disease details
Clinical trials : 9 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 16
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03056742 (ClinicalTrials.gov) | February 20, 2017 | 23/1/2017 | A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease | A Single Arm, Open Label, Multicentric, Clinical Study Assessing the Efficacy and Safety of Stempeucel® (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With CLI Due to Buerger's Disease | Critical Limb Ischemia Due to Buerger's Disease | Biological: Stempeucel(R) | Stempeutics Research Pvt Ltd | NULL | Withdrawn | 18 Years | 65 Years | All | 0 | Phase 2 | India |